The global oncology biopharmaceuticals market is projected to grow at a CAGR of 7.7% from 2025 to 2033, supported by sustained progress in targeted and immune-based treatments, broader biomarker testing, and earlier-line use across major tumor types. Adoption is reinforced by measurable gains in survival and quality-of-life outcomes, expanding treatment-eligible populations, and steady launch activity across solid and hematologic malignancies.
The global non-small cell lung cancer (NSCLC) market is projected to expand at a CAGR of 10.3% from 2025 to 2033, driven by the rising prevalence of lung cancer, increasing adoption of targeted and immunotherapy drugs, and growing investment in oncology research. NSCLC accounts for approximately 85% of all lung cancer cases worldwide, making it a critical area of focus in oncology drug development. Advancements in biomarker-driven therapies and the availability of personalized treatment regimens are reshaping clinical practices and expanding treatment options.
The global cancer treatment facilities market is projected to grow at a CAGR of 7.5% from 2025 to 2033, driven by the increasing incidence of cancer worldwide, rising patient awareness, and expanding healthcare infrastructure across developed and emerging markets. As cancer prevalence continues to rise due to aging populations, lifestyle factors, and environmental exposures, the demand for advanced treatment centers offering comprehensive, multidisciplinary care is accelerating. Cancer treatment facilities today are not limited to isolated services but function as integrated hubs for surgery, chemotherapy, radiotherapy, immunotherapy, and personalized medicine. Furthermore, public-private collaborations, rising healthcare expenditure, and increased government initiatives aimed at early diagnosis and timely intervention are playing a critical role in the proliferation of oncology care centers worldwide.
The global breast cancer therapeutics market is projected to expand at a CAGR of 8.3% from 2025 to 2033, driven by increasing breast cancer prevalence, rapid advancements in targeted therapies, and expanding access to early diagnosis and treatment. Ongoing R&D in immuno-oncology and the rise in precision medicine are contributing significantly to therapeutic innovation. With healthcare systems prioritizing value-based care, pharmaceutical companies are focusing on improving progression-free survival, minimizing adverse effects, and launching biologics and biosimilars that address tumor heterogeneity and therapy resistance.
The microsurgery robot market is experiencing rapid growth, primarily driven by technological advancements in robotic systems, increasing demand for minimally invasive surgeries, and rising incidences of chronic diseases requiring surgical intervention. With a projected Compound Annual Growth Rate (CAGR) of 13.7%, the market is set to expand significantly over the next decade. This growth is further supported by a growing acceptance of robotic assistance in surgical environments and substantial investments in healthcare infrastructure.
The breast cancer liquid biopsy market is expected to grow at a CAGR of 22.7% during the forecast period of 2025 to 2033. Breast cancer liquid biopsy market is a rapidly evolving field that utilizes non-invasive liquid biopsies to detect and monitor breast cancer through blood samples. This method offers a significant advancement over traditional tissue biopsies, providing real-time insights into tumor dynamics and allowing for personalized treatment strategies.
The doxorubicin market is expected to grow at a CAGR of 6.1% during the forecast period of 2025 to 2033. Doxorubicin is a chemotherapy medication widely used in the treatment of various cancers, including breast cancer, bladder cancer, and lymphomas. Known for its potent efficacy in shrinking cancer cells, it belongs to the anthracycline group of drugs and works by interfering with the growth and spread of cancer cells in the body. The market for doxorubicin has observed significant growth driven by the rising incidence of cancer globally, advancements in cancer research, and increasing awareness and accessibility of treatments.
The genitourinary drugs market is expected to grow at a CAGR of 2.2% during the forecast period of 2025 to 2033. Genitourinary drugs market encompasses a range of pharmaceuticals used to treat disorders affecting the urinary tract and the male and female reproductive systems. These conditions include urinary tract infections, erectile dysfunction, renal diseases, bladder cancer, and chronic kidney disease, among others. The market is characterized by a robust pipeline of pharmacological innovations and is driven by increasing prevalence of related diseases, advancements in medical treatments, and rising awareness and healthcare spending globally.
The prostate cancer therapeutics market is expected to grow at a CAGR of 7.3% during the forecast period of 2025 to 2033, driven by an increasing incidence of prostate cancer, advancements in treatment options, and a growing understanding of the disease's biology. The market is expected to continue expanding, influenced by key drivers such as the rising prevalence of prostate cancer among the aging population, technological advancements in therapeutics, and the increasing availability of personalized medicine approaches.
The sirolimus market is expected to grow at a CAGR of 4.2% during the forecast period of 2025 to 2033, driven by factors such as the increasing prevalence of chronic diseases, advancements in drug delivery systems, and expanding applications across different therapeutic areas. While cancer emerged as the leading therapeutic area in 2025, neurological conditions are expected to exhibit the highest growth rate during the forecast period. Geographically, North America and Europe are the key revenue contributors, while Asia Pacific is poised for significant growth.
The oncology drugs market includes pharmaceutical products and advanced therapies used to treat cancer. Major treatment classes include chemotherapy, targeted therapy, immunotherapy, hormonal therapy, monoclonal antibodies, antibody-drug conjugates, cancer vaccines and cell-based treatments. These drugs are used across lung, breast, colorectal, prostate, blood, skin, ovarian, liver and other cancer indications.
The global cancer and oncology drugs market is expected to record strong growth through 2035. One current industry estimate projects the market to increase from approximately USD 214.70 billion in 2026 to USD 554.69 billion by 2035, representing a compound annual growth rate of 11.17%. Growth is supported by targeted treatments, developments in proteomics and continued demand for more effective cancer therapies.
The increasing global incidence of cancer is a major market driver. Population ageing, tobacco use, obesity, environmental exposure and lifestyle-related risk factors are contributing to a growing patient population. Improved screening and diagnostic technologies are also identifying more patients at earlier stages, increasing the number of individuals eligible for pharmaceutical treatment.
Targeted therapies represent an important market segment. These drugs act on specific genes, proteins or pathways involved in tumour development. Biomarker testing and companion diagnostics help physicians identify patients who are more likely to respond to particular treatments. Precision oncology is therefore increasing the connection between diagnostic testing and drug selection.
Immunotherapy continues to change cancer treatment by helping the immune system identify and attack tumour cells. Immune checkpoint inhibitors, CAR-T cell therapies and cancer vaccines are being studied across multiple solid and blood cancers. Combination therapies using immunotherapy with chemotherapy, targeted drugs or radiation are also expanding as companies seek to improve treatment response and patient survival.
Other major trends include antibody-drug conjugates, bispecific antibodies, radiopharmaceuticals and personalized cancer vaccines. Artificial intelligence is being used for target identification, molecule screening, clinical-trial planning and analysis of patient data. Biosimilars are gaining importance as patents expire for established oncology biologics, potentially improving access and increasing price competition.
Market expansion may be restrained by high treatment costs, adverse effects and unequal access to cancer care. Oncology drugs require extensive clinical testing, and unsuccessful trials can result in substantial development losses. Drug resistance may reduce long-term treatment effectiveness and create demand for additional therapies. Reimbursement restrictions and complex regulatory requirements can also delay patient access.
North America remains a major market due to high cancer treatment expenditure, research activity and access to new medicines. Europe maintains a significant position, while Asia-Pacific is expected to record strong growth as cancer incidence, healthcare investment and access to treatment increase.
Acute Market Reports provides oncology drugs market research covering drug classes, cancer indications, routes of administration, distribution channels, development pipelines, competitive conditions and regional opportunities. These reports help pharmaceutical companies, biotechnology firms, investors and healthcare organizations assess market demand and growth prospects through 2035.